



# UNITED STATES PATENT AND TRADEMARK OFFICE

UNITED STATES DEPARTMENT OF COMMERCE  
United States Patent and Trademark Office  
Address: COMMISSIONER FOR PATENTS  
P.O. Box 1450  
Alexandria, Virginia 22313-1450  
www.uspto.gov

APPLICATION NO.	FILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO.
09/992,600	11/13/2001	Stephane Bejanin	91.US4.DIV	9889

23557 7590 06/17/2004

SALIWANCHIK LLOYD & SALIWANCHIK  
A PROFESSIONAL ASSOCIATION  
2421 N.W. 41ST STREET  
SUITE A-1  
GAINESVILLE, FL 32606-6669

EXAMINER

MYERS, CARLA J

ART UNIT	PAPER NUMBER
----------	--------------

1634

DATE MAILED: 06/17/2004

Please find below and/or attached an Office communication concerning this application or proceeding.

## Office Action Summary

**Application No.**

09/992,600

**Applicant(s)**

BEJANIN ET AL.

**Examiner**

Carla Myers

**Art Unit**

1634

-- The MAILING DATE of this communication appears on the cover sheet with the correspondence address --

**Period for Reply**

A SHORTENED STATUTORY PERIOD FOR REPLY IS SET TO EXPIRE 1 MONTH(S) FROM THE MAILING DATE OF THIS COMMUNICATION.

- Extensions of time may be available under the provisions of 37 CFR 1.136(a). In no event, however, may a reply be timely filed after SIX (6) MONTHS from the mailing date of this communication.
- If the period for reply specified above is less than thirty (30) days, a reply within the statutory minimum of thirty (30) days will be considered timely.
- If NO period for reply is specified above, the maximum statutory period will apply and will expire SIX (6) MONTHS from the mailing date of this communication.
- Failure to reply within the set or extended period for reply will, by statute, cause the application to become ABANDONED (35 U.S.C. § 133). Any reply received by the Office later than three months after the mailing date of this communication, even if timely filed, may reduce any earned patent term adjustment. See 37 CFR 1.704(b).

**Status**

- 1) ☐ Responsive to communication(s) filed on \_\_\_\_.
- 2a) ☐ This action is **FINAL**. 2b) ☐ This action is non-final.
- 3) ☐ Since this application is in condition for allowance except for formal matters, prosecution as to the merits is closed in accordance with the practice under *Ex parte Quayle*, 1935 C.D. 11, 453 O.G. 213.

**Disposition of Claims**

- 4) ☒ Claim(s) 14-54 is/are pending in the application.
- 4a) Of the above claim(s) \_\_\_\_ is/are withdrawn from consideration.
- 5) ☐ Claim(s) \_\_\_\_ is/are allowed.
- 6) ☐ Claim(s) \_\_\_\_ is/are rejected.
- 7) ☐ Claim(s) \_\_\_\_ is/are objected to.
- 8) ☒ Claim(s) 14-54 are subject to restriction and/or election requirement.

**Application Papers**

- 9) ☐ The specification is objected to by the Examiner.
- 10) ☐ The drawing(s) filed on \_\_\_\_ is/are: a) ☐ accepted or b) ☐ objected to by the Examiner.  
Applicant may not request that any objection to the drawing(s) be held in abeyance. See 37 CFR 1.85(a).  
Replacement drawing sheet(s) including the correction is required if the drawing(s) is objected to. See 37 CFR 1.121(d).
- 11) ☐ The oath or declaration is objected to by the Examiner. Note the attached Office Action or form PTO-152.

**Priority under 35 U.S.C. § 119**

- 12) ☐ Acknowledgment is made of a claim for foreign priority under 35 U.S.C. § 119(a)-(d) or (f).
- a) ☐ All b) ☐ Some \* c) ☐ None of:
1. ☐ Certified copies of the priority documents have been received.
  2. ☐ Certified copies of the priority documents have been received in Application No. \_\_\_\_.
  3. ☐ Copies of the certified copies of the priority documents have been received in this National Stage application from the International Bureau (PCT Rule 17.2(a)).

\* See the attached detailed Office action for a list of the certified copies not received.

**Attachment(s)**

- |   |   |
|---|---|
| 1) <input type="checkbox"/> Notice of References Cited (PTO-892)                        | 4) <input type="checkbox"/> Interview Summary (PTO-413)                     |
| 2) <input type="checkbox"/> Notice of Draftsperson's Patent Drawing Review (PTO-948)    | Paper No(s)/Mail Date. ____.  |
| 3) <input type="checkbox"/> Information Disclosure Statement(s) (PTO-1449 or PTO/SB/08) | 5) <input type="checkbox"/> Notice of Informal Patent Application (PTO-152) |
| Paper No(s)/Mail Date ____.   | 6) <input type="checkbox"/> Other: ____.                                    |

***RESTRICTION***

1. Restriction to one of the following inventions is required under 35 U.S.C. § 121:

- I. Claims 14-27, 41 and 42, drawn to nucleic acids, vectors and host cells, classified in Class 536, subclass 23.5.
  - II. Claim 28, drawn to a transgenic animal, classified in Class 800, subclass 13.
  - III. Claims 29-40, drawn to proteins, classified in Class 530, subclass 350.
  - IV. Claims 43-46, drawn to antibodies, classified in Class 530, subclass 387.
  - V. Claims 47 and 48, drawn to methods to detect proteins, classified in Class 435, subclass 7.1.
  - VI. Claims 49 and 50, drawn to a method to detect nucleic acids, classified in Class 435, subclass 6.
  - VII. Claim 51 and 52, drawn to methods for identifying modulators of a protein, classified in Class 435, subclass 7.1.
  - VIII. Claims 53, drawn to a method of using a SCPhx polypeptide for biosynthesis of a recombinant heterologous polypeptide, classified in Class 435, subclass 69.1.
  - IX. Claims 54, drawn to a method of using a SCPhx polypeptide for biosynthesis of a recombinant heterologous polypeptide, classified in Class 435, subclass 24.
2. The inventions are distinct, each from the other because of the following reasons:
- Inventions I and II are related as combination and subcombination. Inventions in this relationship are distinct if it can be shown that (1) the combination as claimed does not require the particulars of the subcombination as claimed for patentability, and (2) that the subcombination has utility by itself or in other combinations (MPEP

Art Unit: 1634

§ 806.05(c)). In the instant case, the combination as claimed does not require the particulars of the subcombination as claimed because the transgenic animal is a patentably distinct entity over the nucleic acids since the transgenic animal has its own unique functional and structural characteristics. The subcombination has separate utility such as to serve as a template for DNA or RNA synthesis or as a probe in a hybridization assay.

Inventions I and III are patentably distinct in structure and physicochemical properties. Invention I is drawn to nucleic acids whereas invention III is drawn to proteins. Because nucleic acids are composed of nucleotides and proteins are composed of amino acids, the inventions have different structural and functional properties. Furthermore, the products are utilized in different methodologies, such that nucleic acids may be utilized in hybridization assays, while proteins may be utilized in ligand binding assays or to generate antibodies. Synthesis of the proteins of invention II do not require the particular products of the nucleic acids of invention I since the proteins of invention III can be isolated from natural sources or chemically synthesized.

Inventions I and IV are unrelated. Inventions are unrelated if it can be shown that they are not disclosed as capable of use together and they have different modes of operation, different functions, or different effects (MPEP § 806.04, MPEP § 808.01). In the instant case, the nucleic acids of invention I are not required to make the antibodies of invention IV. Furthermore, the different inventions are not disclosed as capable of use together and have different functions and have different physical and structural properties.

Art Unit: 1634

Inventions I and V, I and VII, I and VIII and I and IX are unrelated. Inventions are unrelated if it can be shown that they are not disclosed as capable of use together and they have different modes of operation, different functions, or different effects (MPEP § 806.04, MPEP § 808.01). In the instant case, the nucleic acids of invention I are not required to practice the methods of inventions V, VII, VIII or IX.

Inventions I and VI are related as product and process of use. The inventions can be shown to be distinct if either or both of the following can be shown: (1) the process for using the product as claimed can be practiced with another materially different product or (2) the product as claimed can be used in a materially different process of using that product (M.P.E.P. § 806.05(h)). In the instant case, the nucleic acids of invention I can be used in a materially different process, such as for synthesizing nucleic acids or proteins, or for therapeutic methods.

Inventions II and III and inventions II and IV are drawn to patentably distinct products. The transgenic animals of invention II are structurally and functionally distinct from the proteins of invention III and the antibodies of invention IV. Further, the products are used in distinct methods, such that the transgenic animals of invention II can be used to study the effects of therapeutic treatment, whereas the proteins and antibodies of inventions II and III, respectively, can be used in ligand binding assays.

Inventions II and V, II and VI, II and VII, II and VIII and II and IX are unrelated. Inventions are unrelated if it can be shown that they are not disclosed as capable of use together and they have different modes of operation, different functions, or different

Art Unit: 1634

effects (MPEP § 806.04, MPEP § 808.01). In the instant case, the transgenic animals of invention II are not required to practice the methods of inventions V, VI, VII, VIII or IX.

Inventions III and IV are patentably distinct in structure in that the proteins of invention III have a different amino acid sequence as compared to the antibodies of invention IV. Furthermore, the products of invention III and IV are utilized in different methodologies, such that the proteins may be utilized in ligand binding assays and the antibodies may be used in therapeutic methods. Synthesis of the antibodies of invention IV does not require the particular products of the proteins of invention II since the antibodies of invention IV can be isolated from natural sources.

Inventions III and V, III and VII, III and VIII, and III and IX are related as product and process of use. The inventions can be shown to be distinct if either or both of the following can be shown: (1) the process for using the product as claimed can be practiced with another materially different product or (2) the product as claimed can be used in a materially different process of using that product (M.P.E.P. § 806.05(h)). In the instant case, the proteins of invention III can be used in a materially different process, such as for generating antibodies or for therapeutic purposes.

Inventions III and VI are unrelated. Inventions are unrelated if it can be shown that they are not disclosed as capable of use together and they have different modes of operation, different functions, or different effects (MPEP § 806.04, MPEP § 808.01). In the instant case, the proteins of invention III are not required to practice the methods of inventions VI.

Art Unit: 1634

Inventions IV and V are related as product and process of use. The inventions can be shown to be distinct if either or both of the following can be shown: (1) the process for using the product as claimed can be practiced with another materially different product or (2) the product as claimed can be used in a materially different process of using that product (M.P.E.P. § 806.05(h)). In the instant case, the antibodies of invention IV can be used in a materially different process, such as for therapeutic uses.

Inventions IV and VI, IV and VII, IV and VIII and IV and IX are unrelated. Inventions are unrelated if it can be shown that they are not disclosed as capable of use together and they have different modes of operation, different functions, or different effects (MPEP § 806.04, MPEP § 808.01). In the instant case, the different inventions are not disclosed as capable of use together because the antibodies of invention IV are not required to practice the methods of invention VI, VII, VIII or IX.

Inventions V, VI, VII, VIII and IX are unrelated to each other. Inventions are unrelated if it can be shown that they are not disclosed as capable of use together and they have different modes of operation, different functions, or different effects (MPEP § 806.04, MPEP § 808.01). In the instant case, the different inventions are drawn to distinct methods, each requiring different reagents, involving different method steps and having different objectives. For example, the method of invention V requires the use of proteins and antibodies, involves the use of performing protein binding assays and accomplishes the objective of detecting the presence of a protein. Invention VII requires the use of a compound that binds to and modulates SCPhx and accomplishes the

Art Unit: 1634

objective of identifying a modulator of SCP<sub>h</sub>x. The method of invention VI requires the use of nucleic acid primers or probes, involves performing amplification or hybridization steps and accomplishes the objective of detecting the presence of a nucleic acid.

Invention VIII involves engineering a recombinant polypeptide, expressing the polypeptide, contacting the polypeptide with SCP<sub>h</sub>x and removing an inactivated C-terminal amino acid to accomplish the objective of synthesizing a recombinant heterologous protein. Invention IX requires removing a C-terminal amino acid from a protein and assaying the function of the protein to accomplish the objective of determining whether removal of the C-terminal amino acid reduces the function of the test protein.

3. Because these inventions are distinct for the reasons given above and have acquired a different status in the art as demonstrated by their different classification and recognized divergent subject matter and because inventions I-IX require different searches that are not co-extensive, examination of these distinct inventions would pose a serious burden on the examiner and therefore restriction for examination purposes as indicated is proper.

4. The examiner has required restriction between product and process claims. Where applicant elects claims directed to the product, and a product claim is subsequently found allowable, withdrawn process claims that depend from or otherwise include all the limitations of the allowable product claim will be rejoined in accordance with the provisions of MPEP § 821.04. **Process claims that depend from or otherwise include all the limitations of the patentable product** will be entered as a matter of



Art Unit: 1634

right if the amendment is presented prior to final rejection or allowance, whichever is earlier. Amendments submitted after final rejection are governed by 37 CFR 1.116; amendments submitted after allowance are governed by 37 CFR 1.312.

In the event of rejoinder, the requirement for restriction between the product claims and the rejoined process claims will be withdrawn, and the rejoined process claims will be fully examined for patentability in accordance with 37 CFR 1.104. Thus, to be allowable, the rejoined claims must meet all criteria for patentability including the requirements of 35 U.S.C. 101, 102, 103, and 112. Until an elected product claim is found allowable, an otherwise proper restriction requirement between product claims and process claims may be maintained. Withdrawn process claims that are not commensurate in scope with an allowed product claim will not be rejoined. See "Guidance on Treatment of Product and Process Claims in light of *In re Ochiai*, *In re Brouwer* and 35 U.S.C. § 103(b)," 1184 O.G. 86 (March 26, 1996). Additionally, in order to retain the right to rejoinder in accordance with the above policy, Applicant is advised that the process claims should be amended during prosecution either to maintain dependency on the product claims or to otherwise include the limitations of the product claims. **Failure to do so may result in a loss of the right to rejoinder.** Further, note that the prohibition against double patenting rejections of 35 U.S.C. 121 does not apply where the restriction requirement is withdrawn by the examiner before the patent issues. See MPEP § 804.01.

Art Unit: 1634

5. Applicant is advised that the response to this requirement to be complete must include an election of the invention to be examined even though the requirement be traversed.


6. Applicant is reminded that upon the cancellation of claims to a non-elected invention, the inventorship must be amended in compliance with 37 C.F.R. § 1.48(b) if one or more of the currently named inventors is no longer an inventor of at least one claim remaining in the application. Any amendment of inventorship must be accompanied by a diligently-filed petition under 37 C.F.R. § 1.48(b) and by the fee required under 37 C.F.R. § 1.17(h).

Any inquiry concerning this communication or earlier communications from the examiner should be directed to Carla Myers whose telephone number is (571) 272-0747. The examiner can normally be reached on Monday-Thursday from 6:30 AM-5:00 PM. A message may be left on the examiner's voice mail service. If attempts to reach the examiner by telephone are unsuccessful, the examiner's supervisor, Gary Benzion, can be reached on (571)-272-0782.

Papers related to this application may be faxed to Group 1634 via the PTO Fax Center using the fax number (703)-872-9306.

Information regarding the status of an application may be obtained from the Patent Application Information Retrieval (PAIR) system. Status information for published applications may be obtained from either Private PAIR or Public PAIR. Status information for unpublished applications is available through Private PAIR only. For more information about the PAIR system, see <http://pair-direct.uspto.gov>. Should you have questions on access to the Private PAIR system, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free).

Carla Myers  
June 14, 2004

  
CARLA J. MYERS  
PRIMARY EXAMINER